Literature DB >> 7412107

Renal toxicity of phosphate in rats.

L L Haut, A C Alfrey, S Guggenheim, B Buddington, N Schrier.   

Abstract

To evaluate the mechanism by which phosphate induces renal injury, we placed uninephrectomized, partially nephrectomized, and intact rats on dietary phosphorus intakes varying between 0.5 and 2% for 18 weeks. None of the animals on a normal phosphorus intake (0.5%) had any abnormalities. Four out of six intact animals on a 1% phosphorus diet had kidney calcium concentrations within the normal range, and only one showed any histologic changes. In contrast, all but one partial and uninephrectomized animals on a 1% phosphorus diet had increased kidney calcium content concentration, and five of the six studied had histologic changes. The degree of calcification and histologic changes in the uninephrectomized animals on a 1% phosphorus diet was similar to that found in the intact animals on a 2% phosphorus diet. Animals on a 3% phosphorus diet plus disodium ethane-1-hydroxy-1-1-diphosphonate (EHDP) had significantly less calcification and histologic changes than did animals on a similar diet without EHDP. Conclusion. As renal functional mass is reduced, the nephrotoxicity of phosporus is greatly enhanced. Phosphorus-induced renal injury is mediated through calcium phosphate deposition in the kidney. This results from intrarenal caused, because the kidney calcification can be related to phosphate excreted per functional unit rather than plasma phosphate concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7412107     DOI: 10.1038/ki.1980.85

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  60 in total

1.  Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.

Authors:  Jessica Houston; Kelsey Smith; Tamara Isakova; Nicole Sowden; Myles Wolf; Orlando M Gutiérrez
Journal:  J Ren Nutr       Date:  2012-03-09       Impact factor: 3.655

Review 2.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

Review 3.  Dietary Phosphorus Intake and the Kidney.

Authors:  Alex R Chang; Cheryl Anderson
Journal:  Annu Rev Nutr       Date:  2017-06-14       Impact factor: 11.848

4.  Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients.

Authors:  Hee Jung Jeon; Yong Chul Kim; Seokwoo Park; Clara Tammy Kim; Jongwon Ha; Duck Jong Han; Jieun Oh; Chun Soo Lim; In Mok Jung; Curie Ahn; Yon Su Kim; Jung Pyo Lee; Young Hoon Kim
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

5.  Serum fibroblast growth factor-23 is associated with incident kidney disease.

Authors:  Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

Review 6.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

7.  The biomarker niche for fibroblast growth factor 23 testing in CKD.

Authors:  Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

8.  Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.

Authors:  Alex R Chang; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2014-06-14       Impact factor: 8.860

9.  No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Authors:  Rajnish Mehrotra; Carmen A Peralta; Shu-Cheng Chen; Suying Li; Michael Sachs; Anuja Shah; Keith Norris; Georges Saab; Adam Whaley-Connell; Bryan Kestenbaum; Peter A McCullough
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

Review 10.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.